Jy O

Jy O. Background Pazopanib a multitargeted tyrosine kinase inhibitor has singleagent activity in patients with advanced nonadipocytic softtissue sarcoma We investigated the effect of pazopanib on progressionfree survival in patients with metastatic nonadipocytic softtissue sarcoma after failure of standard chemotherapy.

We would like to show you a description here but the site won’t allow us.

Pazopanib for metastatic softtissue sarcoma (PALETTE): a

.